131 related articles for article (PubMed ID: 21831725)
1. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report.
Matrana MR; Ng C; Rao P; Lim ZD; Tannir NM
Clin Genitourin Cancer; 2011 Dec; 9(2):137-9. PubMed ID: 21831725
[No Abstract] [Full Text] [Related]
2. Pazopanib in renal cell carcinoma.
Sternberg CN
Clin Adv Hematol Oncol; 2010 Apr; 8(4):232-3. PubMed ID: 20505644
[No Abstract] [Full Text] [Related]
3. Nursing considerations for patients receiving pazopanib for renal cell carcinoma.
Becze E
ONS Connect; 2012 Feb; 27(2):16-7. PubMed ID: 22375508
[No Abstract] [Full Text] [Related]
4. Everolimus and pazopanib: two new drugs for renal cell cancer.
Med Lett Drugs Ther; 2010 May; 52(1337):33-4. PubMed ID: 20431519
[No Abstract] [Full Text] [Related]
5. Pazopanib in renal cell carcinoma.
Ward JE; Stadler WM
Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
[TBL] [Abstract][Full Text] [Related]
6. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Nieto M; Borregaard J; Ersbøll J; ten Bosch GJ; van Zwieten-Boot B; Abadie E; Schellens JH; Pignatti F
Clin Cancer Res; 2011 Nov; 17(21):6608-14. PubMed ID: 21976546
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
Sonpavde G; Hutson TE; Sternberg CN
Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
[TBL] [Abstract][Full Text] [Related]
8. NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma.
Griffiths C; Hay N; Sutcliffe F; Stevens A
Lancet Oncol; 2011 Mar; 12(3):221-2. PubMed ID: 21495242
[No Abstract] [Full Text] [Related]
9. Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.
Bourdeanu L; Twardowski P; Pal SK
Clin J Oncol Nurs; 2011 Oct; 15(5):513-7. PubMed ID: 21951737
[TBL] [Abstract][Full Text] [Related]
10. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
Jacobs C; Kim DW; Straka C; Timmerman RD; Brugarolas J
J Clin Oncol; 2013 Mar; 31(7):e114-7. PubMed ID: 23319695
[No Abstract] [Full Text] [Related]
11. Symptomatic cardiac metastasis responding to pazopanib in a patient with renal cell carcinoma.
Behzadigohar R; Rosenthal MA; Tran B
Can J Urol; 2015 Jun; 22(3):7824-6. PubMed ID: 26068633
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib: therapeutic developments.
Limvorasak S; Posadas EM
Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.
Cella D; Pickard AS; Duh MS; Guerin A; Mishagina N; Antràs L; Neary MP; McCann L; Hodge R; Sternberg CN
Eur J Cancer; 2012 Feb; 48(3):311-23. PubMed ID: 21689927
[TBL] [Abstract][Full Text] [Related]
14. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
Asaithambi G; Peters BR; Hurliman E; Moran BP; Khan AS; Taylor RA
J Clin Pharm Ther; 2013 Apr; 38(2):175-6. PubMed ID: 23210935
[TBL] [Abstract][Full Text] [Related]
15. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
16. [Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy].
Rexer H
Urologe A; 2011 Apr; 50(4):489-92. PubMed ID: 21472622
[No Abstract] [Full Text] [Related]
17. Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma.
Bonate PL; Suttle AB
Cancer Chemother Pharmacol; 2013 Jul; 72(1):231-40. PubMed ID: 23715625
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
Xu CF; Bing NX; Ball HA; Rajagopalan D; Sternberg CN; Hutson TE; de Souza P; Xue ZG; McCann L; King KS; Ragone LJ; Whittaker JC; Spraggs CF; Cardon LR; Mooser VE; Pandite LN
J Clin Oncol; 2011 Jun; 29(18):2557-64. PubMed ID: 21576632
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy for sarcomatoid renal cell carcinoma.
Pagliaro LC; Tannir N; Sircar K; Jonasch E
Expert Rev Anticancer Ther; 2011 Jun; 11(6):913-20. PubMed ID: 21707288
[TBL] [Abstract][Full Text] [Related]
20. Sarcomatoid chromophobe renal cell carcinoma with osteosarcoma-like differentiation which presented as a retroperitoneal mass: a case report.
Sari A; Evcım G; Ermete M; Gür S
Turk Patoloji Derg; 2011 May; 27(2):164-8. PubMed ID: 21630206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]